AGW Settlement for Nicholas and Flekke Limited each take 2.1% stakes in Antigenika, snakebite therapy firm
Published
AGW Settlement for Nicholas entered Antigenika with a 2.1% holding in ordinary shares.
Flekke Limited also entered with a 2.1% ordinary-share holding.
HSAR Superannuation Fund joined the register with a 0.5% holding in ordinary shares.
Half Brother Capital entered with a 0.3% ordinary-share holding.
The register expanded during the period. The confirmation statement was filed on 14 September 2026, covering changes from 16 February to 11 September 2026.
Shareholder data
Source: Companies House confirmation statement (CS01) — period to , filed .
Changes in this confirmation statement
| Type | Shareholder | Shares | Change | Share classes |
|---|---|---|---|---|
| New shareholder | FLEKKE LIMITED | 8,695 | — | ORDINARY 8,695 |
| New shareholder | HSAR SUPERANNUATION FUND | 2,173 | — | ORDINARY 2,173 |
| New shareholder | HALF BROTHER CAPITAL | 1,304 | — | ORDINARY 1,304 |
Current shareholders (4)
| Shareholder | Total shares | Share classes |
|---|---|---|
| FLEKKE LIMITED | 8,695 | ORDINARY 8,695 |
| HSAR SUPERANNUATION FUND | 2,173 | ORDINARY 2,173 |
| HALF BROTHER CAPITAL | 1,304 | ORDINARY 1,304 |
| SPUNMED CONSULTING LIMITED | 873 | ORDINARY 873 |
Similar companies
Companies with the most similar business descriptions.
- Venomite LtdBiotech · MedTech
- Venom Technologies LimitedBiotech · Drug Discovery · Life Sciences
- Buzz Biolabs Ltd.Skincare · Biotech
- International Therapeutic Proteins LimitedBiotech · Pharma · Life Sciences
- Vespula Therapeutics LtdBiotech · Drug Discovery
- Capsid Biotechnology LtdBiotech · Pharma · Drug Discovery
More rounds like this
Contact the editorial team at editorial@fundingspotter.com